title: Building a better sphingosine kinase-1 inhibitor.
abstract: Sphingosine 1-phosphate (S1P) is currently one of the most intensely studied lipid mediators. Interest in S1P has been propelled by the development of fingolimod, an S1P receptor agonist prodrug, which revealed both a theretofore unsuspected role of S1P in lymphocyte trafficking and that such modulation of the immune system achieves therapeutic benefit in multiple sclerosis patients. S1P is synthesized from sphingosine by two SphKs (sphingosine kinases) (SphK1 and SphK2). Manipulation of SphK levels using molecular biology and mouse genetic tools has implicated these enzymes, particularly SphK1, in a variety of pathological processes such as fibrosis, inflammation and cancer progression. The results of such studies have spurred interest in SphK1 as a drug target. In this issue of the Biochemical Journal, Schnute et al. describe a small molecule inhibitor of SphK1 that is both potent and selective. Such chemical tools are essential to learn whether targeting S1P signalling at the level of synthesis is a viable therapeutic strategy.
authors.affiliation: Department of Pharmacology, University of Virginia, Charlottesville, 22908, USA. krl2z@virginia.edu
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Lynch
mesh_terms: D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism*; D000432:Methanol; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors*; D011759:Pyrrolidines / Q000494:pharmacology*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism; D013450:Sulfones / Q000494:pharmacology*; D000099157:Sphingosine Kinase
chemical_list: D008246:Lysophospholipids; D000432:Methanol; D017853:Phosphotransferases (Alcohol Group Acceptor); D011759:Pyrrolidines; D013110:Sphingosine; D013450:Sulfones; D000099157:Sphingosine Kinase; C573330:PF-543; C060506:sphingosine 1-phosphate